The place of beta-blockers in the treatment of arterial hypertension in 2017: is all so bad?

G.D. Radchenko

Abstract


This article is the review of the literature data about the effectiveness and safety of beta-blockers in arterial hypertension treatment. There were analyzed the influence of beta-blockers on cardiovascular events, central blood pressure and arterial stiffness, glucose and lipid metabolism, target organ damage and quality of life in patients with arterial hypertension. There was concluded that adverse effect rate of beta-blockers is not high in clinical trials and is exaggerated by general practitioners. In patients with arterial hypertension and indications, the beta-blocker treatment is more useful than no treatment, including in patients with diabetes mellitus, metabolic syndrome, the elderly, persons with chronic obstructive pulmonary diseases. If there is a high risk of adverse reactions, the beta-blockers with vasodilation are more benefit. Special stress was done on positive influence of carvedilol.

Keywords


arterial hypertension; antihypertensive therapy; beta-blockers; carvedilol; review

References


Ощепкова Е.В. Роль β-блокаторов в лечении артериальной гипертензии // Атмосфера. Кардиология. — 2005. — № 3. — С. 39-42.

Adler A.I., Stratton I.M., Neil H. et al; on behalf of the UK Prospective Study group. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study // BMJ. — 2000. — Vol. 321. — P. 412-419.

Bradley H., Wiysonge C., Volmink J. et al. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis // J. Hypertens. — 2006. — Vol. 24. — P. 2131-2141.

Hansson L., Hender T., Lund-Johansen P. et al. Randomised trial of effects of calcium antagonistscompared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study // Lancet. — 2000. — Vol. 356. — P. 359-365.

Krause T., Lovibond K., Caulfield M. et al. Management of hypertension: summary of NICE guildelines // BMJ. — 2011. — Vol. 343. — doi: 10.1136/bmj.d4891.

2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // Journal of Hypertension. — 2013. — № 31. — Р. 1281-1357. — doi: 10.1097/01.hjh.0000431740.32696.cc.

Радченко А.Д. Бета-блокаторы в лечении артериальной гипертензии: за и против // Артериальная гипертензия. — 2012. — № 6(26). — С. 91-117.

Leinck J.R. In introduction to cardiovascular physio­logy. — London: Butterworth, 1991. — 279 p.

Menghini F. The role of beta-blocker therapy in the treatment of arterial hypertension. First International Symposium Hypertension 1996: One Medicine, Two Cultures.

Жарінов О. Фармакологічні відмінності та критерії вибору β-адреноблокаторів // Ліки України. — 2004. — № 9. — С. 93-97.

http://www.reuters.com/article/2011/05/31/us-beta-blockers-idUSTRE74U6OD20110531.

Pon C.K., Lane J.R., Sloan E.K., Halls M.L. The 2-adrenoceptor activates a positive cAMP-calcium feedforward loop to drive breast cancer cell invasion // The FASEB Journal. — 2015. — № 30(3). — 1144. — DOI: 10.1096/fj.15-277798.

Messerli F., Grossman E., Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the Elderly? // JAMA. — 1998. — Vol. 279. — P. 1903-1907.

Lever A., Brennan P. MRC trial of treatment in elderly hypertensives // High Blood Press. — 1992. — Vol. 1. — P. 132-137.

Bangalore S., Messerli F.H., Kostis J.B., Pepine C.J. Cardiovascular protection using beta blockers: a critical review of the evidence // J. Am. Coll. Cardiol. — 2007. — Vol. 50. — P. 563-572F.

Messerli F., Bangalore S., Julius S. Risk/Benefit assessment of beta-blockers and diuretics precludes their use for first line therapy in hypertension // Circulation. — 2008. — Vol. 117. — P. 2706-2715.

Messerli F., Grossman E. Beta-blocker therapy and depression // JAMA. — 2002. — Vol. 288. — P. 1845-1846.

Messerli F.H., Beevers D.G., Franklin S.S., Picke­ring T.G. β-Blockers in hypertension — the emperator has no clothes: an open letter to present and prospective drafters of new guidelines for the treatment of hypertension // Am. J. Hypertens. — 2003. — Vol. 16. — P. 870-873.

Messerli F.H., Bangalore S., Yao S.S., Steinberg J.S. Cardioprotection with beta-blockers: myths, facts and Pascal’s wager // J. Intern. Med. — 2009 Sep. — № 266(3). — Р. 232-41. — doi: 10.1111/j.1365-2796.2009.02140.x.

Elliott W., Meyer P. Incident diabetes in clinical trials of antihypertensive drugs: network meta-analysis // Lancet. — 2007. — Vol. 369. — P. 201-207.

Bangalore S., Steg G., Deedwania P., Crowley K., ­Eagle K., Goto S., Ohman M., Cannon C., Smith S. Jr, Zeymer U., Hoffman E., Messerli F., Bhatt D.; for the REACH Registry Investigators. Blocker Use and Clinical Outcomes in Stable Outpatients With and Without Coronary Artery Disease // JAMA. — 2012. — № 308(13). — Р. 1340-1349.

Kotecha D., Krum H., Manzano L., Cleland J., Lip G., Coats A., Andersson B., Kirchhof P., Lueder T., Wedel H., Rosano G., Shibata M., Rigby A., Flather M. Оn behalf of the Beta-Blockers in Heart Failure Collaborative Group Efficacy of β-blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis // JAMA. — 2013. — № 310(17). — Р. 1851-1852. — doi: 10.1001/jama.2013.277510.

Mareev Yu., Cleland J. Should β-Blockers Be Used in Patients With Heart Failureand Atrial Fibrillation? // Clin. Ther. — 2015. — № 37. — Р. 2215-2224. — http://dx.doi.org/10.1016/j.clinthera.2015.08.017.

Parikh V., Bhatt D., King S., M.D. Do Angioplasty Patients Really Need beta-blocker drug? // JACC: Cardiovascular Interventions. — 2016 Aug. — № 16.

Edelman J.M., Lyle P.A., ZhAng Z. Letter to the editor // Ann. Intern. Med. — 2004. — Vol. 140. — P. 29.

Staeson J.A., Wang J.G., Thigs L. Cardiovascular prevention and blood pressure reduction // J. Hypertens. — 2003. — Vol. 21. — P. 1055.

Neal B., MacMahon S., Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. blood Pressure Lowering Treatment Trialists’ collaboration // Lancet. — 2000. — Vol. 356. — P. 1955.

Law M., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the p context of expectations from prospective revention of cardiovascular disease: meta-analysis of 147 randomised trials in the epidemiological studies // BMJ. — 2009. — Vol. 338. — P. 1665.

Lund L., Benson L., Dahlström U., Edner M., Friberg L. Association between use of β-blockers and outcomes in patients with heart failure and preserved ejection fraction // JAMA. — 2014. — № 312(19). — Р. 2008-2018. — doi: 10.1001/jama.2014.15241.

Bhatia V., Bajaj N.S., Sanam K. et al. Beta-blocker use and 30-day all-cause readmission in Medicare beneficiaries with systolic heart failure // Am. J. Med. — 2015. — DOI: 10.1016/j.amjmed.2014.11.036.

Rosendorff C., Lackland D., Allison M., Aronow W., Black H., Blumenthal R., Cannon C., de Lemos J., Elliott W., Fin­deiss L., Gersh B., Gore J., Levy D., Long J., O’Connor C., O’Gara P., Ogedegbe G., Oparil S.,White W. and on behalf of the American Heart Association, American College of Cardiology, and American Society of Hypertension. Treatment of Hypertension in Patients With Coronary Artery Disease A Scientific Statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension // Circulation. — 2015. — № 131. — Р. e435-e470. — https://doi.org/10.1161/CIR.0000000000000207.

Zhang H., Yuan X., Zhang H., Chen S., Zhao Y., Hua K., Rao C.,Wang W., Sun H., Hu S., Zheng Z. Efficacy of Chronic β-Blocker Therapy for Secondary Prevention on Long-Term Outcomes After Coronary Artery Bypass Grafting Surgery // Circulation. — 2015. — https://doi.org/10.1161/CIRCULATIONAHA.114.014209.

Wiysonge C.S., Bradley H.A., Volmink J. et al. Beta-blockers for hypertension (Review). — John Wiley & Sons, Ltd., 2012. — 77 p.

Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs overview and meta-analyses // Journal of Hypertension. — July 2015. — Vol. 33, Is. 7. — Р. 1321-1341. — doi: 10.1097/HJH.0000000000000614.

Ong H. Beta-blockers in hypertension and cardiovascular disease // BMJ. — 2007. — Vol. 334. — P. 946-949.

Carlberg B., Samuelsson O., Lindholm L.H. Atenolol in hypertension: is it a wise hoice? // Lancet. — 2004 Nov 6–12. — № 364(9446). — Р. 1684-9.

Lindholm L.H., Carlberg B., Samuelsson O. Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis // Lancet. — 2005. — Vol. 366. — P. 1545-1553.

Roman M.J., Devereux R.B., Kizer J.R. et al. High central pulse pressure is independently associated with adverse cardiovascular outcome the strong heart study // J. Am. Coll. Cardiol. — 2009. — Vol. 54. — P. 1730-1734.

Williams B., Lacy P. for the CAFE and the ASCOT ­(Anglo-Scandinavian Cardiac Outcomes Trial) Investigators Impact of Heart Rate on Central Aortic Pressures and Hemodynamics Analysis From the CAFE (Conduit Artery Function Evaluation) Study: CAFE-Heart Rate // J. Am. Coll. Cardiol. — 2009. — Vol. 54. — P. 705-713.

Nakamura M., Sato K., Nagano M. Estimation of aortic systolic blood pressure in community-based screening: the relationship between clinical characteristics and peripheral to central blood pressure differences // J. Hum. Hypertens. — 2005. — Vol. 19. — P. 251-253.

Sharman J.E., Stowasser M., Fassett R.G., Marwick T.H., Franklin S.S. Central blood pressure measurement may improve risk stratification // J. Hum. Hypertens. — 2008. — Vol. 22. — P. 838-844.

Wilkinson I., Franklin S., Hall I. et al. Pressure Amplification Explains Why Pulse Pressure is unrelated to risk in young subjects // Hypertens. — 2001. — Vol. 38. — P. 1461-1466.

Williams B., Lacy P.S., Thom S.M. et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study // Circulation. — 2006. — Vol. 113. — P. 1213-1225.

Charlotte H., Manisty & Alun D. Hughes. Meta-analysis of the comparative effects of different classes of antihypertensive agents on brachial and central systolic blood pressure, and augmentation index. — DOI: 10.1111/j.1365-2125.2012.04342.x.

Fox K., Ford I., Steg P.G., Tardif J.C., Tendera M., Ferrari R.; SIGNIFY Investigators. Ivabradine in stable coronary artery disease without clinical heart failure // N. Engl. J. Med. — 2014. — № 371. — Р. 1091-1099. — doi: 10.1056/ NEJMoa1406430.

Fox K., Ford I., Steg P.G., Tendera M., Ferrari R.; BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and leftventricular systolic dysfunction (BEAUTIFUL): a randomised, doubleblind, placebo-controlled trial // Lancet. — 2008. — № 372. — Р. 807-816. — doi: 10.1016/ S0140-6736(08)61170-8.

Rimoldi S.F., Messerli F.H., Cerny D., Gloekler S., Traupe T., Laurent S., Seiler C. Selective Heart Rate Reduction With Ivabradine Increases Central Blood Pressure in Stable Coronary Artery Disease // Hypertension. — 2016 Jun. — № 67(6). — Р. 1205-10. — doi: 10.1161/HYPERTENSIONAHA.116.07250.

Matsui Y., Eguchi K., O’Rourke M. et al. Differential Effects Between a Calcium Channel Blocker and a Diuretic When Used in Combination With Angiotensin II Receptor Blocker on Central Aortic Pressure in Hypertensive Patients // Hypertension. — 2009. — Vol. 54. — P. 716-723.

Poole-Wilson P.A., Swedberg K., Cleland J.G.F.; for the COMET investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial // Lancet. — 2003. — Vol. 362. — P. 7-13.

Polуnia J., Barbosa L., Silva J., Bertoquini S. Different patterns of peripheral versus central blood pressure in hypertensive patients treated with [beta]-blockers either with or without vasodilator properties or with angiotensin receptor blockers // Blood Pressure Monitoring. — 2010. — Vol. 15. — P. 235-239.

Niren K. Shah, Steven M. Smith, Wilmer W. Carvedilol Reduces Aortic Wave Reflection and Improves Left Ventricular/Vascular Coupling: A Comparison With Atenolol (CENTRAL Study) // The Journal of Clinical Hypertension. — 2011. — Vol. 13. — P. 917-924.

Ong K., Delerme S., Pannier B. et al.; on behalf of the investigators. Аоtic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: a meta-analysis of individual data in 294 patients // Journal of Hypertension. — 2011. — Vol. 29. — P. 1034-1042.

Катеринчук І., Катеринчук В. Артеріальна гіпертензія у хворих на цукровий діабет. — К., 2005. — 169 с.

Sharma A.M., Pischon T., Hardt S. et al. Hypothesis: beta-adrenergic receptor blockers and weight gain. A systematic analysis // Hypertension. — 2001. — Vol. 37, № 2. — P. 250-254.

Bakris G.L., Fonseca V., Katholi R.E., McGill J.B., Messerli F.H., Phillips R.A., Raskin P., Wright J.T. Jr, Oakes R., Lukas M.A., Anderson K.M., Bell D.S.; GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial // JAMA. — 2004 Nov 10. — № 292(18). — Р. 2227-36.

Радченко Г.Д. Критерії, детермінуючі фактори та резерви ефективного лікування хворих з артеріальною гіпертензією за даними проспективного та ретроспективного спостереження: Автореф. док. дисертації // Науковий світ. — К., 2008. — 43 с.

Kveiborg В., Hermann T., Atheline Major-Pedersen A. et al. Metoprolol compared to carvedilol deteriorates insulin-sti­mulated endothelial function in patients with type 2 diabetes — a randomized study // Cardiovascular Diabetology. — 2010. — Vol. 9. — P. 21-30.

Hauf-Zachariou U., Widmann L., Zilsdorf B., Hennig M., Lang P.D. A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia // Eur. J. Clin. Pharmacol. — 1993. — Vol. 45. — P. 95-100.

Дзяк Г.В., Ханюков А.А. Современные представления о роли бета-адреноблокаторов в лечении хронической сердечной недостаточности: особенности клинического применения карведилола // Укр. мед. часопис. — 2009. — № 4(72). — С. 17-23.

Barzilay J.I. et al.; ALLHAT Collaborative Research Group. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment // Arch. Intern. Med. — 2006. — Vol. 166. — P. 2191-2201.

Kostis J.B. et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes // Am. J. Cardiol. — 2005. — Vol. 95. — P. 29-35.

Verdecchia P., Reboldi G., Angeli F. et al. Adverse Prognostic Significance of New Diabetes in Treated Hypertensive Subjects // Hypertension. — 2004. — Vol. 43. — P. 963-969.

Hansson L., Lindholm L., Niskanen L. et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity in hypertension: the Captopril Preventional Project (CAPP) randomised trial // Lancet. — 1999. — Vol. 353. — P. 611-616.

Haas S.J., Vos T., Gilbert R.E., Krum H. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials // Am. Heart J. — 2003. — Vol. 146. — P. 848-853.

Ryden L., Standl E., Bartnik M. еt al. Guidelines on diabetes, pre-diabetes, and cardiovascular disease: executive summary: the Task Force on Diabetes and Cardiovascular Disease of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes // Eur. Heart J. — 2007. — Vol. 28. — P. 88-136.

Schmieder R.E., Martus P., Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-ana­lysis of randomized double-blind studies // JAMA. — 1996. — № 275. — Р. 1507-13.

Klingbeil A., Schneider M., Martus P. et al. A meta-ana­lysis of the effects of treatment on left ventricular mass in essential hypertension // The American Journal of Medicine. — 2003. — Vol. 115. — P. 41-46.

Verza M., Ammendola S., Cambardella A., Scoti G., Vescio S., Tortoriello R., Amato L., Cerqua G., Varricchio G. Regression of left ventricular hypertrophy in hypertensive elderly patients with carvedilol // Arch. Gerontol. Geriatr. — 1996. — № 22(Suppl. 1). — Р. 143-7. — DOI: 10.1016/0167-4943(96)86927-5.

Neglia D., De Maria R., Masi S. et al. Effects of long-term treatment with carvedilol on myocardial blood fow in idiopathic dilated cardiomyopathy // Heart. — 2007. — Vol. 93. — P. 808-813.

Sugioka K., Hozumi T., Takemoto Y. et al. Early reco­very of impaired coronary fow reserve by carvedilol therapy in patients with idiopathic dilated cardiomyopathy: a serial transthoracic Doppler echocardiographic study // J. Am. Coll. Cardiol. — 2005. — Vol. 45. — P. 318-319.

Sugioka K., Hozumi T., Takemoto Y. et al. Relation of early improvement in coronary flow reserve to late recovery of left ventricular function after beta-blocker therapy in patients with idiopathic dilated cardiomyopathy // Am. Heart J. — 2007. — Vol. 153. — P. 1080.

2003 Eropean Society of Hypertention — Eropean Society of Cardiology guidelines for management of arterial hypertension // J. Hypertention. — 2003. — Vol. 21. — P. 1011-1053.

National Kidney Foundation. Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, classification and stratification. Executive summary. — New York: K/DOQI Lear­ning System (KLS)TM, 2002. — 94 p.

Weidmann P., Boehlen M., de Courten M. Effects of different antihypertensive drugs on human proteinuria // Nephrol. Dial. Transplant. — 1993. — Vol. 8. — P. 582-584.

Parving H.H., Rossing P. The use of antihypertensive agents in prevention and treatment of diabetic nephropathy // Curr. Opin Nephrol. Hypertens. — 1994. — Vol. 3. — P. 292-300.

Morelli E., Loon N., Meyer T., Peters W., Myers B.D. Effects of convertingenzyme inhibition on barrier function in diabetic glomerulopathy // Diabetes. — 1990. — Vol. 39. — P. 76-82.

Rudberg S., Østerby R., Bangstad H.J., Dahlquist G., Persson B. Effect of angiotensin converting enzyme inhibitor or beta blocker on glomerular structural changes in young microalbuminuric patients with type 1 (insulin-dependent) diabetes mellitus // Diabetologia. — 1999. — Vol. 42. — P. 589-595.

Bjorck S., Mulec H., Johnsen S.A., Norden G., Aurell M. Renal protective effect of enalapril in diabetic nephropathy // BMJ. — 1992. — Vol. 304. — P. 339-342.

Elving L.D., Wetzels J.M.F., van Lier H.J.J. et al. Captopril and atenolol are equally effective in retarding progression of diabetic neph-ropathy // Diabetologia. — 1994. — Vol. 37. — P. 604-609.

Sawicki P.T.; for the Diabetes Teaching and Treatment Programmes Working Group. Stabilisation of glomerular filtration rate over 2 years in patients with diabetic nephropathy under intensified therapy regimens // Nephrol. Dial. Transplant. — 1997. — Vol. 12. — P. 1890-1909.

Agarwal R., Sinha A.D., Pappas M.K., Abraham T.N., Tegegne G.G. Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial // Nephrol. Dial. Transplant. — 2014. — № 29. — Р. 672-681.

Badve S.V., Roberts M.A., Hawley C.M. et al. Effects of beta-adrenergic antagonists in рatients with chronic kidney di­sease: a systematic review and meta-analysis // J. Am. Coll. Cardiol. — 2011. — Vol. 58. — P. 1152-1161.

Kalaitzidis R., Bakris G. Should nephrologists use beta-blockers? A perspective // Nephrol. Dial. Transplant. — 2009. — Vol. 24. — Р. 701-702.

Abraham W.T., Tsvetkova T., Lowes B.D. et al. Carvedilol improves renal hemodynamics in patients with chronic heart failure // J. Card. Fail. — 1998. — Vol. 98(Suppl. 1). — P. 378-379.

Tomita K., Marumo F. Effect of long-term carvedilol therapy on renal function in essential hypertension // J. Cardiovasc. Pharmacol. — 1992. — Vol. 19(Suppl. 1). — P. 97-101.

Ito H., Nagatomo Y., Kohno T. et al. Differential effects of carvedilol and metoprolol on renal function in patients with heart failure // Circ. J. — 2010. — Vol. 74. — P. 1578-1583.

Agrawal B., Wolf K., Berger A., Luft F.C. Effect of anti­hypertensive treatment on qualitative estimates of microalbumi­nuria // J. Hum. Hypertens. — 1996. — Vol. 10. — P. 551-555.

Dupont A.G. Carvedilol and the kidney // Clin. Investig. — 1992. — Vol. 70(Suppl. 1). — P. 127-131.

Fassbinder W., Quarder O., Waltz A. Treatment with carvedilol is associated with a signifcant reduction in microalbuminuria: a multicentre randomised study // Int. J. Clin. Pract. — 1999. — Vol. 53. — P. 519-522.

Marchi F., Ciriello G. Effcacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria: a multicenter, randomized, open-label, controlled study versus ­atenolol // Adv. Ther. — 1995. — Vol. 12. — P. 212-221.

Leonetti G., Egan C. Use of carvedilol in hypertension: an update // Vascular. Health and Risk Management. — 2012. — Vol. 8. — P. 307-322.

Zanchetti A., Bond M.G., Hennig M. et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial // Circulation. — 2002. — Vol. 106. — P. 2422-2427.

Olsen M.H., Wachtell K., Neland K. et al. Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy // Blood Press. — 2005. — Vol. 14. — P. 177-183.

Wang Ji-Guang, Staessen J., Li Yan et al. Carotid Intima-Media Thickness and Antihypertensive Treatment A Meta-Analysis of Randomized Controlled Trials // Stroke. — 2006. — Vol. 37. — P. 1933-1940.

Marfella R., Siniscalchi M., Nappo F. et al. Regression of carotid atherosclerosis by control of morning blood pressure peak in newly diagnosed hypertensive patients // Am. J. Hypertens. — 2005. — Vol. 18. — P. 308-331.

Wu T.C., Chen Y.H., Leu H.B. et al. Carvedilol, a pharmacological antioxidant, inhibits neointimal matrix metalloproteinase-2 and -9 in experimental atherosclerosis // Free Radic. Biol. Med. — 2007. — Vol. 43. — P. 1508-1522.

Guan Y.Y., Ye B.H., Lu H.H. et al. Study of carvedilol on plaque stability in carotid atherosclerotic rabbits transfected by p53 gene // Zhonghua Xin Xue Guan Bing Za Zhi. — 2007. — Vol. 35. — P. 63-68.

McMurray J., Cohen-Solal A., Dietz R. et al. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice // Eur. J. Heart Fail. — 2005. — Vol. 7. — P. 710-721.

The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failu­re Association (HFA) of the ESC. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure // European Heart Journal. — 2016. — № 37. — Р. 2129-2200. — doi: 10.1093/eurheartj/ehw128.

Kuller L.H., Ockene J.K., Townsend M., Browner W., Meilahn E., Wentworth D.N. The epidemiology of pulmonary function and COPD mortality in the multiple risk factor intervention trial // Am. Rev. Respir. Dis. — 1989. — Vol. 140. — P. 76-81.

Vilkman S., Keistinen T., Tuuponen T., Kivela S.L. Survival and cause of death among elderly chronic obstructive pulmonary disease patients after first admission to hospital // Respiration. — 1997. — Vol. 64. — P. 281-284.

Sin D.D., Man S.F. Chronic obstructive pulmonary di­sease as a risk factor for cardiovascular morbidity and mortality // Proc. Am. Thorac. Soc. — 2005. — Vol. 2. — P. 8-11.

Andrus M.R., Holloway K.P., Clark D.B. Use of beta-blockers in patients with COPD // Ann. Pharmacother. — 2004. — Vol. 38. — P. 142-145.

Short P., Lipworth S., Elder D. et al. Effect of β blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study // BMJ. — 2011. — Vol. 342. — P. d2549.

Gottlieb S.S., McCarter R.J., Vogel R.A. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction // N. Engl. J. Med. — 1998. — Vol. 339. — P. 489-497. — DOI: 10.1056/NEJM199808203390801.

Dickstein K., Cohen-Solal A., Filippatos G. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) // Eur. Heart J. — 2008. — Vol. 29. — P. 2388-2442.

Salpeter S.R., Ormiston T.M., Salpeter E.E. Cardio­selective beta-blockers in patients with reactive airway disease: a meta-analysis // Ann. Intern. Med. — 2002. — Vol. 137. — P. 715-725.

Evdokimov V., Radzevich A., Evdokimova A., Kovalenko E. Study of clinical efficacy of nebivolol and carvedilol admini­stration in complex therapy of chronic heart failure due to coronary heart disease combined with chronic obstructive pulmonary disease // European Journal of Heart Failure Supplements. — 2010. — Vol. 9. — P. S20.

Hawkins N., MacDonald M., Petrie M. еt al. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial // European Journal of Heart Failure. — 2009. — Vol. 11. — P. 684-690.

European Lung Foundation. “Beta-blockers could reduce the risk of COPD exacerbations” // Science Daily. — 14 March 2016. — www.sciencedaily.com/releases/2016/03/160314091003.htm.

Onishi K. Total management of chronic obstructive pulmonary disease (COPD) as an independent risk factor for cardiovascular disease // J. Cardiol. — 2017 Mar 18. — pii: S0914-5087(17)30055-2. — doi: 10.1016/j.jjcc.2017.03.001.

Morales D., Lipworth B., Donnan P., Jackson C., ­Guthrie B. Respiratory effect of beta-blockers in people with asthma and cardiovascular disease: population-based nested case control study // BMC Medicine. — 2017. — № 15. — 18. — DOI: 10.1186/s12916-017-0781-0.

Erdmann E. Safety and tolerability of beta-blockers: pre­judices ad reality // Eur. Heart J. — 2009. — Vol. 11 (Suppl. A). — P. 21-25.

Radack K., Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with perip­heral arterial disease. A meta-analysis of randomized controlled trials // Arch. Intern. Med. — 1991. — Vol. 151. — P. 1769-1776.

Paravastu S.C., Mendonca D.A., da Silva A. Beta blockers for peri-pheral arterial disease // Eur. J. Vasc. Endovasc. Surg. — 2009. — Vol. 38. — P. 66-70.

Feringa H., van Waning V., Bax J. et al. Cardioprotective medications associated with improved survive in patients with peripheral arterial disease // Journal of the American College of Cardiology. — 2006. — Vol. 47, № 6. — P. 1182-1187.

Wendt T. Acute hemodynamic effects of carvedilol in comparison with propranolol in patients with coronary heart di­sease // J. Molecular Medicine. — 1992. — Suppl. 2. — P. 93-97.

Espinola-Klein C., Weisser G., Jagodzinski A. et al. β-Blockers in Patients With Intermittent Claudication and Arterial Hypertension Results From the Nebivolol or Metoprolol in Arterial Occlusive Disease Trial // Hypertension. — 2011. — Vol. 58. — P. 148-154.

Jaffe A., Chen Y., Kisch E.S. et al. Erectile dysfunction in hypertensive subjects: assessment of potential determinants // Hypertension. — 1996. — Vol. 28. — P. 859-862.

Giuliano F.A., Leriche A., Jaudinot E. et al. Prevalence of erectile dysfunction among 7689 patients with diabetes, hypertension, or both // Urology. — 2004. — Vol. 64. — P. 1196-1201.

Doumas M., Tsakiris A., Douma S. et al. Factors affec­ting the increased prevalence of erectile dysfunction in Greek hypertensive compared to normotensive individuals // J. Androl. — 2006. — Vol. 27. — P. 469-477.

Toblli J.E., Stella I., Inserra F., Ferder L., Zeller F., Mazza O.N. Morphological changes in cavernous tissue in spontaneously hypertensive rats // Am. J. Hypertens. — 2000. — Vol. 13. — P. 686-692.

Toblli J.E., Stella I., Mazza O.N. et al. Protection of cavernous tissue in male spontaneously hypertensive rats: beyond blood pressure control // Am. J. Hypertens. — 2004. — Vol. 17. — P. 516-522.

Ushiyama M., Morita T., Kuramochi T., Yagi S., Katayama S. Erectile dysfunction in hypertensive rats results from impairment of the relaxation evoked by neurogenic carbon monoxide and nitric oxide // Hypertens. Res. — 2004. — Vol. 27. — P. 253-261.

Grimm R.H., Grandits G.A., Prineas R.J. et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women: Treatment of Mild Hypertension Study (TOMHS) // Hypertension. — 1997. — Vol. 29. — P. 8-14.

Viigma M., Doumas M., Vlachopoulos C. et al. Hypertension and sexual dysfunction: time to act // J. Hypertens. — 2011. — Vol. 29. — P. 403-407.

Shiri R., Koskimäki J., Häkkinen J. et al. Cardiovascular Drug Use and the Incidence of Erectile Dysfunction // Int. J. Impot. Res. — 2007. — 19(2). — 208-212.

Prisant L.M., Weir M.R., Frishmanwh et al. Self reported Sexual Dysfunction in Men and Woman Treated With Bisoprolol, Hydrochlorothiazide, Enalapril, Placebo, or Bisoprolol/Hydrochlorothiazide // J. Clin. Hypertens. — 1999. — Vol. 1. — P. 22-26.

Fogari R., Preti P., Derosa G. et al. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men // Eur. J. Clin. Pharmacol. — 2002. — Vol. 58. — P. 177180.

http://www.ehealthme.com/ds/carvedilol/erectile+dysfunction.

Nur-Mammadova G., Mustafayev I. State of autonomic nervous system, penile hemodynamic and sexual function in men with arterial hypertension. Abstract // J. Hypertens. — 2010. — Vol. 28. — P. 475e.

Silvestri А., Galetta Р., Cerquetani Е. et al. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo // Eur. Heart J. — 2003. — Vol. 24. — P. 1928-1932.

Komajda M., Follath F., Swedberg K. et al. The EuroHeart Failure Survey programme — a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment // Eur. Heart J. — 2003. — Vol. 24. — P. 464-474.

Deedwania P.C., Gottlieb S., Ghali J.K., Waagstein F., Wikstrand J.C.; for the MERIT-HF Study Group. Efficacy, safety and tolerability of fbetag-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure // Eur. Heart J. — 2004. — Vol. 25. — P. 1300-1309.

Erdmann E., Lechat P., Verkenne P., Wiemann H. Results from post hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure // Eur. J. Heart Fail. — 2001. — Vol. 3. — P. 469-479.

Flather M.D., Shibata M.C., Coats A.J. et al. Ran-domi­zed trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) // Eur. Heart J. — 2005. — Vol. 26. — P. 215-225.

Krum H., Hill J., Fruhwald F. et al. Tolerability of beta-blockers in elderly patients with chronic heart failure: the COLA II study // Eur. J. Heart Fail. — 2006. — Vol. 8. — P. 302-307.

Düngen H., Apostolović S., Inkrot S., Tahirović E., Töpper A., Mehrhof F., Prettin C., Putniković B., Nešković A., Krotin M., Sakač D., Lainščak M., Edelmann F., Wachter R., Rau T., Eschenhagen T., Doehner W., Anker S., Waagstein F., Herrmann-Lingen C., Gelbrich G., Dietz R.; on behalf of the CIBIS-ELD investigators and Project Multicentre Trials in the Competence Network Heart Failure. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial // European Journal of Heart Failure. — 2011. — № 13. — Р. 670-680. — DOI: 10.1093/eurjhf/hfr020.

Steinman M.A., Zullo M.R., Lee Y. et al. Association of beta-blockers with functional outcomes, death, and rehospitalization in older nursing home residents after acute myocardial infarction // JAMA Intern. Med. — 2016. — DOI: 10.1001/jamainternmed.2016.7701.

Valdes A., Abhishek A., Muir K., Zhang W., Maciewicz R., Doherty M. Beta-blocker use associates with lower prevalence of joint pain and lower opioid requirement in people with osteoarthritis // Arthritis Care Res. — 2016 Oct 1. — doi: 10.1002/acr.23091.

Aronow et al. Hypertension in Elderly // JACC. — 2011. — Vol. 57. — Р. 2037-2114.

Poldermans D., Boersma E., Bax J.J., Poldermans D., Boersma E., Bax J.J. et al. Dutch echocardiographic cardiac risk evaluation applying stress echocardiography study group. Bisoprolol reduces cardiac death and myocardial infarction in high risk patients as long as 2 years after successful major vascular surgery // Eur. Heart J. — 2001. — Vol. 22. — P. 1353-1358.

Poldermans D., Boersma E., Bax J.J., Thomson I., van de Ven L., Blankensteijn J. et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high risk patients undergoing vascular surgery. Dutch echocardiographic cardiac risk evaluation applying stress echocardiography study group // N. Engl. J. Med. — 1999. — Vol. 341. — P. 1789-1794.

Yue T.L., Lysko P.G., Barone F. et al. Carvedilol, a new antihypertensive with unique antioxidant activity: potential role of cerebroprotection // Ann. N. Y. Acad. Sci. — 1994. — Vol. 738. — P. 230-242.

https://www.statista.com/statistics/242661/top-hypertension-drugs-in-the-us-based-on-prescriptions-dispensed-2011-2012.

Effect of Carvedilol and Nebivolol on Oxidative Stress-Related Parameters and Endothelial Function in Patients With Essential Hypertension // Basic & Clinical Pharmacologgy & Toxicology. — 2012. — № 111. — Р. 309-316.

Messerli F.H., Grossman E. Вeta-Blockers in hypertension: is carvedilol different? // Am. J. Cardiol. — 2004 May 6. — № 93(9A). — Р. 7B-12B. — DOI: 10.1016/j.amjcard.2004.01.020.

DiNicolantonio J.J., Lavie C.J., Fares H., Menezes A.R., O’Keefe J.H. Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebivolol) // Am. J. Cardiol. — 2013 Mar 1. — № 111(5). — Р. 765-9.

Hiremath S., Lokikere S. Carvedilol as nephroprotective agent: a meta-analysis of randomized controlled trials // International J. of Basic & Clinical Pharmacology. — 2016. — Vol. 5. — Р. 769-774. — DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20161517.

Cice G., Ferrara L., D’Andrea A., D’Isa S., Di B.A., Cittadini A. et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial // J. Am. Coll. Cardiol. — 2003. — № 41. — Р. 1438-1444.

Tanaka K., MD; Tanaka H., Kamiya C., Katsuragi S., Sawada M., Tsuritani M., Yoshida M., Iwanaga N., Yoshimatsu J., Ikeda T. Beta-Blockers and Fetal Growth Restriction in Pregnant Women With Cardiovascular Disease // Circ. J. — 2016. — № 80. — Р. 2221-2226.

American Diabetes Association Standards of Medical Care in Diabetesd 2017 // Diabetes Care. — January 2017. — Vol. 40(Suppl.). — Р. 1-142.

Wang J., Ono K., Dickstein D., Arrieta-Cruz I., Zhao W., Qian X., Lamparello A., Subnani R., Ferruzzi M., Pavlides C., Ho L., Hof P., Teplow D., Pasinetti G. Carvedilol as a potential novel agent for the treatment of Alzheimer’s disease // Neurobiol. Aging. — 2011 Dec. — № 32(12). — Р. 2321.e1-2321.e12. — doi: 10.1016/j.neurobiolaging.2010.05.004.

Kim S., Kim T., Sohn J., Um S., Seo Y., Baik S., Kim M., Jang J., Jeong S., Lee B., Kim Y., Suk K., Kim D. A Randomi­zed, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis // The American Journal of Gastroenterology. — 2016. — № 111. — Р. 1582-1590. — doi: 10.1038/ajg.2016.327.

Hjalmarson A., Elmfekdt D., Herlitz J., Holmberg S., Malek I., Nyberg G. Effect on mortality of metoprolol in acute myocardial infarction, a double-blind randomised trial // Lancet. — 1981. — Vol. II. — P. 123-7.

The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction // N. Engl. J. Med. — 1985. — Vol. 6. — P. 199-226.

ISIS-1 (First International Study on Infarct Survival) Collaborative Group. Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction // Lancet. — 1986. — Vol. II. — P. 57-66.

Malmberg K., Herlitz J., Hjalmarson Е., Ryden L. Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction // Eur. Heart J. — 1989. — Vol. 10. — P. 423-428.

Beta-blocker Heart Attack Trial Research Group. A randomised trial of propranolol in patients with acute myocardial infarction. I. Mortality results // JAMA. — 1982. — Vol. 247. — P. 1707-1714.

Gundersen T., Kjekshus J.K. Timolol treatment after myocardial infarction in diabetic patients // Diabetes Care. — 1983. — Vol. 6. — P. 285-290.

Kjekshus J., Glipin E., Cali G., Blackey, Henning H., Ross J. Diabetic patients and beta-blockers after acute myocardial infarction // Eur. Heart J. — 1990. — Vol. 11. — P. 43-50.




DOI: https://doi.org/10.22141/2224-1485.2.52.2017.101292

Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru